Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis.
Kobayashi
Kazuhiko
K
Department of Hematology and Rheumatology, JR Tokyo General Hospital, Tokyo, Japan.
Kami
Masahiro
M
Murashige
Naoko
N
Kishi
Yukiko
Y
Fujisaki
George
G
Mitamura
Tadayuki
T
D000935:Antifungal Agents / Q000009:adverse effects*; D001228:Aspergillosis / Q000150:complications / Q000188:drug therapy*; D025141:Drug Resistance, Fungal; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications; D008172:Lung Diseases, Fungal / Q000209:etiology* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000009:adverse effects*; D014230:Triazoles / Q000009:adverse effects*; D065819:Voriconazole; D020096:Zygomycosis / Q000139:chemically induced / Q000209:etiology*
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole